ストックスクリーナーアプリを入手
21.64
3.52%
-0.79
前日終値:
$22.43
開ける：
$22.46
24時間の取引高:
4.16M
Relative Volume:
3.00
時価総額：
$2.71B
収益：
$247.00M
当期純損益:
$-353.00M
株価収益率:
-6.557
EPS:
-3.3003
ネットキャッシュフロー:
$-484.00M
1週間 パフォーマンス:
-1.50%
1か月 パフォーマンス:
+13.95%
6か月 パフォーマンス:
+74.66%
1年 パフォーマンス:
+138.59%
1日の値動き範囲:
$21.64
$22.75
1週間の範囲:
$21.64
$23.16
52週間の値動き範囲:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
名前
Arcus Biosciences Inc
セクター
電話
(510) 694-6200
住所
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ALNY, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
21.64 | 2.71B | 247.00M | -353.00M | -484.00M | -3.3003 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-12 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | アップグレード | Goldman | Neutral → Buy |
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 開始されました | H.C. Wainwright | Neutral |
| 2024-10-08 | 開始されました | Wells Fargo | Overweight |
| 2022-11-18 | 開始されました | BofA Securities | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-11-23 | 開始されました | Evercore ISI | Outperform |
| 2020-04-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-09-27 | 開始されました | Mizuho | Buy |
| 2019-05-24 | 再開されました | Citigroup | Buy |
| 2018-10-09 | 開始されました | Wedbush | Outperform |
| 2018-04-09 | 開始されました | Citigroup | Buy |
| 2018-04-09 | 開始されました | Goldman | Neutral |
| 2018-04-09 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Arcus Biosciences Inc (RCUS) 最新ニュース
(RCUS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Arcus Biosciences, Inc. (RCUS) Stock Price Prediction for 2026, 2030-2040 - Traders Union
B of A Securities Maintains Arcus Biosciences (RCUS) Neutral Recommendation - MSN
Arcus Biosciences, Inc. $RCUS Shares Bought by Decheng Capital LLC - MarketBeat
Here’s what analysts think about Arcus Biosciences (RCUS) - MSN
WINTON GROUP Ltd Purchases Shares of 92,229 Arcus Biosciences, Inc. $RCUS - MarketBeat
Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion - simplywall.st
Arcus Biosciences (RCUS) Valuation After Casdatifan Kidney Cancer Data Pipeline Update And Earnings - Sahm
How (RCUS) Movements Inform Risk Allocation Models - Stock Traders Daily
New Arcus Biosciences hires receive stock options at $23.43 - Stock Titan
Arcus Biosciences at Leerink Conference: Casdatifan’s Promising Data By Investing.com - Investing.com Canada
RCUS: Casdatifan delivers higher efficacy and durable responses in RCC, with strong upcoming trial data - TradingView
Is Arcus Biosciences Inc still a buy after recent gainsWeekly Trading Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Performance Recap: Can Arcus Biosciences Inc disrupt its industryJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - baoquankhu1.vn
Vanguard Group Inc. Increases Stock Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Aug Sectors: Is Arcus Biosciences Inc in a long term uptrendQuarterly Performance Summary & Free High Return Stock Watch Alerts - baoquankhu1.vn
Citigroup Raises Arcus Biosciences (RCUS) Price Target to $45 | - GuruFocus
Citigroup Raises Arcus Biosciences (NYSE:RCUS) Price Target to $45.00 - MarketBeat
Fisher Asset Management LLC Acquires 640,990 Shares of Arcus Biosciences, Inc. $RCUS - MarketBeat
RCUS SEC FilingsArcus Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Arcus (RCUS) Q4 2025 Earnings Call Transcript - AOL.com
RCUS Stock Jumps 17.5% Despite $353M Net Loss: What $34 Fair Value Signals - TIKR.com
Arcus Biosciences (RCUS) Is Up 27.0% After Casdatifan Kidney Cancer Data And TKI-Free Strategy Shift - simplywall.st
The Analyst Verdict: Arcus Biosciences In The Eyes Of 5 Experts - Sahm
Arcus Biosciences: Q4 Beat And Casdatifan’s Story So Far (NYSE:RCUS) - Seeking Alpha
RCUS Analyst Rating Updated by Leerink Partners | RCUS Stock New - GuruFocus
Arcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
Arcus Biosciences (NYSE:RCUS) Shares Up 9.5%Here's What Happened - MarketBeat
Arcus Biosciences (NYSE:RCUS) Given "Buy" Rating at HC Wainwright - MarketBeat
Arcus Biosciences Puts Casdatifan Kidney Cancer Data At Center Stage - Yahoo Finance
Arcus Biosciences (RCUS) Analyst Rating Reaffirmed with Target P - GuruFocus
HC Wainwright Brokers Increase Earnings Estimates for RCUS - MarketBeat
Performance Recap: Is Arcus Biosciences Inc stock a buy or sellEarnings Miss & Community Consensus Trade Alerts - baoquankhu1.vn
Can Arcus Biosciences Inc stock double in the next year2025 Growth vs Value & Accurate Technical Buy Alerts - baoquankhu1.vn
Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Rebound And Casdatifan Expectations - simplywall.st
Arcus Biosciences Q4 Earnings Call Highlights - Yahoo Finance
Arcus Biosciences (RCUS) Posts US$106 Million Q4 Loss Reinforcing Bearish Profitability Narratives - Sahm
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Arcus Biosciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:RCUS) 2026-02-27 - Seeking Alpha
Arcus Biosciences (RCUS) Stock Analysis: Is A 65% Upside In Reach? - DirectorsTalk Interviews
MRGPRX2 antagonists disclosed in Arcus Biosciences patent - BioWorld MedTech
FY2030 Earnings Estimate for RCUS Issued By HC Wainwright - MarketBeat
Trading Systems Reacting to (RCUS) Volatility - Stock Traders Daily
Cancer and immune drug developer Arcus Biosciences offers March webcast - Stock Titan
Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals - simplywall.st
Arcus Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Arcus Biosciences earnings beat by $0.21, revenue fell short of estimates - Investing.com Canada
Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Call Highlights: S - GuruFocus
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Arcus Biosciences Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Arcus Biosciences beats EPS expectations in Q4 2025 - Investing.com Nigeria
Arcus Biosciences Inc (RCUS) 財務データ
収益
当期純利益
現金流量
EPS
0.37%
大文字化:
|
ボリューム (24 時間):